Addition of Radium-223 to Enzalutamide Significantly Improves rPFS and OS in mCRPC
Radium-223 plus enzalutamide significantly improved radiological progression-free survival (rPFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases, according to PEACE-3 trial data. The combination also extended time to next systemic treatment (TTNT) but did not affect time to pain progression or first symptomatic skeletal event (SSE). Use of a bone-protecting agent was mandatory. Safety data showed higher rates of adverse events in the combination arm, with no drug-related deaths.
Related Clinical Trials
Reference News
Radium-223 plus enzalutamide significantly improved radiological progression-free survival (rPFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases, according to PEACE-3 trial data. The combination also extended time to next systemic treatment (TTNT) but did not affect time to pain progression or first symptomatic skeletal event (SSE). Use of a bone-protecting agent was mandatory. Safety data showed higher rates of adverse events in the combination arm, with no drug-related deaths.